Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 366

Sort by

Sort Order Select

Journal Articles

Evaluation of Clinical Risk Factors and Thrombosis-Related Biomarkers in Newly Diagnosed Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. the Observational Roadmat-CAT-MM Study

Patrick Van Dreden, Loula Papageorgiou, Eleftheria Lefkou, Despina Fotiou, Efstathios Kastritis, Evangelos Terpos, Aurelie Rousseau, Michele Sabbah, Matthieu Grusse, Ismail Elalamy, Elisabeth Mbemba, Meletios Athanasios Dimopoulos, Grigoris Gerotziafas

Blood (2023) 142 (Supplement 1): 5404.

https://doi.org/10.1182/blood-2023-187055

Published: 2023

Journal Articles

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Blood (2023) 142 (Supplement 1): 3401.

https://doi.org/10.1182/blood-2023-188538

Published: 2023

Journal Articles

Treatment with Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic and Metabolic Complete Response to Achieve Long-Term Progression Free Survival Among Patients Presenting with Extra-Medullary Disease: A European Myeloma Network Study (EMN19)

Meral Beksac, Tulin Tuglular, Francesca Gay, Roberto Mina, Eirini Katodritou, Ali Unal, Michele Cavo, Guner Hayri Ozsan, Vincent H.J. Van Der Velden, H. Berna Beverloo, Michael Vermeulen, Mark van Duin, Guldane Cengiz Seval, Omur Gokmen Sevindik, Serena Merante, Kyriaki Manousou, Pieter Sonneveld, Elena Zamagni, Evangelos Terpos

Blood (2023) 142 (Supplement 1): 1956.

https://doi.org/10.1182/blood-2023-178533

Published: 2023

Journal Articles

Incidence of Second Primary Malignancies in Patients with AL Amyloidosis and the Impact of Disease Stage and Therapies

Efstathios Kastritis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Despina Fotiou, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Rodanthi Syrigou, Asimina Papanikolaou, Hariklia Gakiopoulou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos

Blood (2023) 142 (Supplement 1): 3404.

https://doi.org/10.1182/blood-2023-189521

Published: 2023

Journal Articles

Long-Term Safety and Efficacy Results of Belantamab Mafodotin Plus Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Part 1 Analysis from the Phase 1/2 Belard Trial

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Maria Douvali, Giorgos Psarros, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 4765.

https://doi.org/10.1182/blood-2023-173064

Published: 2023

Journal Articles

Prothrombotic Profile in Patients with Active Multiple Myeloma and the Impact of Immunomodulators: The Roadmap-MM Study

Patrick Van Dreden, Loula Papageorgiou, Eleftheria Lefkou, Despina Fotiou, Efstathios Kastritis, Evangelos Terpos, Aurelie Rousseau, Michele Sabbah, Matthieu Grusse, Elisabeth Mbemba, Ismail Elalamy, Meletios Athanasios Dimopoulos, Grigoris Gerotziafas

Blood (2023) 142 (Supplement 1): 1203.

https://doi.org/10.1182/blood-2023-186645

Published: 2023

Journal Articles

A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment

Evangelos Terpos, Efstathios Kastritis, Argiris Symeonidis, Anastasia Pouli, Sosana Delimpasi, Eirini Katodritou, Eleftheria Hatzimichael, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Kyriaki Manousou, Maria Gavriatopoulou, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 6712.

https://doi.org/10.1182/blood-2023-173185

Published: 2023

Journal Articles

Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study

Blood (2023) 142 (Supplement 1): 208.

https://doi.org/10.1182/blood-2023-177564

Published: 2023

Journal Articles

Bortezomib-Cyclophosphamide-Dexamethasone (VCD) Vs Bortezomib-Lenalidomide-Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma: A Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)

Blood (2023) 142 (Supplement 1): 4734.

https://doi.org/10.1182/blood-2023-179416

Published: 2023

Journal Articles

Curability of Light Chain (AL) Amyloidosis with Conventional Dose Regimens

Foteini Theodorakakou, Despina Fotiou, Vasiliki Spiliopoulou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Rodanthi Syrigou, Asimina Papanikolaou, Charikleia Gakiopoulou, Erasmia Psimenou, Tina Bagratuni, Alexandra Papathoma, Maria Gavriatopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos, Efstathios Kastritis

Blood (2023) 142 (Supplement 1): 6756.

https://doi.org/10.1182/blood-2023-189926

Published: 2023

Journal Articles

Evaluation of a Novel Method for the Assessment of Ocular Adverse Events and Associated Functional Impact in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial

Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Maria Douvali, Stavros Gkolfinopoulos, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 6726.

https://doi.org/10.1182/blood-2023-173074

Published: 2023

Journal Articles

A Phase II Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Progressing on or after One Line of Lenalidomide-Containing Therapy

Evangelos Terpos, Maria Gavriatopoulou, Eirini Katodritou, Argiris Symeonidis, Anastasia Pouli, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Ioannis Ninos, Sosana Delimpasi, Eleftheria Hatzimichael, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 6728.

https://doi.org/10.1182/blood-2023-173170

Published: 2023

Journal Articles

Prevalence of Peripheral Neuropathy (PN) Among Patients with Asymptomatic Monoclonal Gammopathies: A Clinical & Electrophysiological Study

Panagiotis Zis, Rodanthi Syrigou, Stella Fanouraki, Maria Gavriatopoulou, Despina Fotiou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Maria Roussou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Evangelos Terpos, Meletios A. Dimopoulos, Efstathios Kastritis

Blood (2023) 142 (Supplement 1): 529.

https://doi.org/10.1182/blood-2023-180673

Published: 2023

Journal Articles

Update Analysis of Central Nervous System Multiple Myeloma Prognosis and Survival: A Real-World Multi-Institutional Study of the Greek Myeloma Study Group

Blood (2023) 142 (Supplement 1): 1981.

https://doi.org/10.1182/blood-2023-181029

Published: 2023

Journal Articles

Loss of Mir-221/222 Cluster Expression Results in Short-Term Disease Progression and Poor Post-Treatment Outcome in Multiple Myeloma

Konstantinos Soureas, Christos Minopoulos, Maria-Alexandra Papadimitriou, Panagiotis Malandrakis, Panagiotis Adamopoulos, Ioannis Ntanasis-Stathopoulos, Aristea-Maria Papanota, Maria Gavriatopoulou, Diamantis C Sideris, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Andreas Scorilas, Evangelos Terpos, Margaritis Avgeris

Blood (2023) 142 (Supplement 1): 3353.

https://doi.org/10.1182/blood-2023-186495

Published: 2023

Journal Articles

Low Levels of Circulating Tumor Cells Correlate with Favorable Clinical Outcome and Unique Biological Features in Newly Diagnosed Multiple Myeloma Patients

Ioannis V Kostopoulos, Ioannis Ntanasis-Stathopoulos, Pantelis Rousakis, Evangelos Eleutherakis-Papaiakovou, Chrysanthi Panteli, Panagiotis Malandrakis, Nikolaos Angelis, Nikolaos Kanellias, Georgia Dimitrakopoulou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Maria Gavriatopoulou, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Ourania Tsitsilonis, Evangelos Terpos

Blood (2023) 142 (Supplement 1): 880.

https://doi.org/10.1182/blood-2023-186259

Published: 2023

Journal Articles

An Updated Analysis of Ocular Adverse Events and Vision-Related Functioning in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial

Blood (2023) 142 (Supplement 1): 6720.

https://doi.org/10.1182/blood-2023-173072

Published: 2023

Journal Articles

CXCR4 S338X Promotes Resistance to Second Generation BTK Inhibitor and BCL-2 Inhibitor in WM Cells

Eleni Kalafati, Nefeli Mavrianou Koutsoukou, Alexandra Papadimou, Kostantina Taouxi, Meletios A. Dimopoulos, Evangelos Terpos, Nicholas P. Anagnou, Efstathios Kastritis, Tina Bagratuni

Blood (2023) 142 (Supplement 1): 6600.

https://doi.org/10.1182/blood-2023-180658

Published: 2023

Journal Articles

Natural Killer Cells Are Active Against Myeloma, Leukemia or Lymphoma Cells with Loss of Tumor Suppressor Genes

Olga Dashevsky, Sara Gandolfi, Olli Dufva, Ricardo De Matos Simoes, Jani Huuhtanen, Benjamin G. Barwick, Ryosuke Shirasaki, Michal Sheffer, Aidan Culhane, Jonathan D. Licht, Christine-Ivy Liacos, Evangelos Terpos, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Lawrence H. Boise, Francisca Vazquez, Matti Kankainen, Satu Mustjoki, Constantine S Mitsiades

Blood (2023) 142 (Supplement 1): 6842.

https://doi.org/10.1182/blood-2023-189570

Published: 2023

Journal Articles

A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Evangelos Terpos, Efstathios Kastritis, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Nikolaos Kanellias, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis Papaiakovou, Stavros Gkolfinopoulos, Kyriaki Manousou, Meletios A. Dimopoulos

Blood (2022) 140 (Supplement 1): 12616–12617.

https://doi.org/10.1182/blood-2022-162241

Published: 2022

NARROW

Evaluation of Clinical Risk Factors and Thrombosis-Related Biomarkers in Newly Diagnosed Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. the Observational Roadmat-CAT-MM Study

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Treatment with Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic and Metabolic Complete Response to Achieve Long-Term Progression Free Survival Among Patients Presenting with Extra-Medullary Disease: A European Myeloma Network Study (EMN19)

Incidence of Second Primary Malignancies in Patients with AL Amyloidosis and the Impact of Disease Stage and Therapies

Long-Term Safety and Efficacy Results of Belantamab Mafodotin Plus Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Part 1 Analysis from the Phase 1/2 Belard Trial

Prothrombotic Profile in Patients with Active Multiple Myeloma and the Impact of Immunomodulators: The Roadmap-MM Study

A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment

Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study

Bortezomib-Cyclophosphamide-Dexamethasone (VCD) Vs Bortezomib-Lenalidomide-Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma: A Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)

Curability of Light Chain (AL) Amyloidosis with Conventional Dose Regimens

Evaluation of a Novel Method for the Assessment of Ocular Adverse Events and Associated Functional Impact in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial

A Phase II Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Progressing on or after One Line of Lenalidomide-Containing Therapy

Prevalence of Peripheral Neuropathy (PN) Among Patients with Asymptomatic Monoclonal Gammopathies: A Clinical & Electrophysiological Study

Update Analysis of Central Nervous System Multiple Myeloma Prognosis and Survival: A Real-World Multi-Institutional Study of the Greek Myeloma Study Group

Loss of Mir-221/222 Cluster Expression Results in Short-Term Disease Progression and Poor Post-Treatment Outcome in Multiple Myeloma

Low Levels of Circulating Tumor Cells Correlate with Favorable Clinical Outcome and Unique Biological Features in Newly Diagnosed Multiple Myeloma Patients

An Updated Analysis of Ocular Adverse Events and Vision-Related Functioning in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial

CXCR4 S338X Promotes Resistance to Second Generation BTK Inhibitor and BCL-2 Inhibitor in WM Cells

Natural Killer Cells Are Active Against Myeloma, Leukemia or Lymphoma Cells with Loss of Tumor Suppressor Genes

A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only